Sanofi's launch of Xyzal Allergy 24HR in the US helped remedy its slumping consumer health product business with more than $43m sales in the first quarter as the division's overall revenues grew nearly 5% to $1.5bn.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?